CEVEC closes major financing round to further expand and commercialize its viral vector manufacturing platform
Funding strengthens CEVEC’s leading role in viral vector manufacturing technology
CEVEC’s technology allows for industrial scale manufacturing of AAV vectors and opens the field for gene therapy applications in a wide range of indications
Cologne, Germany, April 16, 2019
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the successful closing of a Series D financing round with new and existing investors. The funding will be allocated to the expansion and commercialization of CEVEC’s CAP®GT-based stable adeno-associated viral (AAV) vector production platform and to the broadening of the Company’s technology portfolio.